Navigation Links
Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
Date:7/9/2008

TORONTO, July 9 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced progress made in the Virulizin(R) development program, including the publication of two research studies on the Virulizin(R) mode of action and the issuance of a new patent for Virulizin(R) in Mexico.

"Publication of these two studies in international scientific journals adds significantly to our previous studies on Virulizin(R) anticancer mechanisms and activities," commented Dr. Aiping Young, Lorus' President and CEO. "In addition, allowance of a new patent strengthens the intellectual property position for this product, and protects the potential for expanding the use to other cancer indications in this jurisdiction."

New Virulizin(R) patent issued in Mexico

The patent, titled "Immunomodulating Compositions from Bile for the Treatment of Immune System Disorders", protects methods of treating several cancers using Virulizin(R). This is the second patent issued in Mexico for Virulizin(R), and extends patent protection for Virulizin(R) in this country to 2016. Similar patents for Virulizin(R) have also been issued in a number of other countries worldwide, including Canada, Australia, and the United States.

Virulizin(R) is currently approved for the treatment of malignant melanoma in Mexico. The new patent provides protection for the potential treatment with Virulizin(R) of additional cancers, including ovarian and lung cancers. Virulizin(R) composition, manufacturing process, and use in the treatment of cancers are also protected in Mexico under an earlier patent issued to Lorus in 2003.

Virulizin(R) has demonstrated significant anticancer activity against a wide range of human cancers in preclinical studies, and has been tested in several clinical
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... 14 Boston Scientific Corporation (NYSE: ... offering of $2 billion aggregate principal amount of its ... The public offering consists of $850 million of 4.50 ... percent notes due January 2020 and $300 million of ... plans to use the net proceeds for general corporate ...
(Date:12/14/2009)... of Brookfield Engineering’s Powder Flow Tester – helping Brookfield move ... footprint and more compact design. , ... ... US-based thermoforming company, has completed the delivery of Brookfield Engineering’s ... to a plastic enclosure with a smaller footprint and more ...
(Date:12/11/2009)... Colo., December 10, 2009 miRagen Therapeutics, Inc., ... by developing innovative microRNA-based therapeutics for cardiovascular and ... demonstrating that microRNA-206 (miR-206) plays a crucial role ... or Lou Gehrig,s disease) and in neuromuscular synaptic ... the December 11 issue of the journal ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer therapeutics company, ... the,US, the Tulane Cancer Center, New Orleans, ... clinical study of Alpharadin in men with,castration-resistant ... has metastasized to the skeleton. , ... SYMptomatic Prostate CAncer) study is a,double-blind, randomized, ...
Breaking Biology Technology:Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4
... Inc. (OTC Bulletin Board: CSBR), a company engaged ... specific data to,enhance the value of oncology drugs, ... Under the terms of the private investment,Champions Biotechnology ... at $1.75 per share. There were no fees ...
... Company Taking ... Actions to Address New Challenges, KENILWORTH, N.J., April 23 ... for the first,quarter of 2008, reviewed progress on its ongoing ... addressed recent,events affecting the Merck/Schering-Plough cholesterol franchise., "The first ...
... Dutch researchers in Amsterdam have collaborated using for the ... Depression research. They used postmortem human brain tissue that ... purposes and investigated a region in the basal part ... be of crucial importance for the development of symptoms ...
Other Biology Technology:Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share 2Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share 3Schering-Plough Reports Financial Results for First Quarter of 2008 2Schering-Plough Reports Financial Results for First Quarter of 2008 3Schering-Plough Reports Financial Results for First Quarter of 2008 4Schering-Plough Reports Financial Results for First Quarter of 2008 5Schering-Plough Reports Financial Results for First Quarter of 2008 6Schering-Plough Reports Financial Results for First Quarter of 2008 7Schering-Plough Reports Financial Results for First Quarter of 2008 8Schering-Plough Reports Financial Results for First Quarter of 2008 9Schering-Plough Reports Financial Results for First Quarter of 2008 10Schering-Plough Reports Financial Results for First Quarter of 2008 11Schering-Plough Reports Financial Results for First Quarter of 2008 12Schering-Plough Reports Financial Results for First Quarter of 2008 13Schering-Plough Reports Financial Results for First Quarter of 2008 14Schering-Plough Reports Financial Results for First Quarter of 2008 15Schering-Plough Reports Financial Results for First Quarter of 2008 16Schering-Plough Reports Financial Results for First Quarter of 2008 17Schering-Plough Reports Financial Results for First Quarter of 2008 18Schering-Plough Reports Financial Results for First Quarter of 2008 19
(Date:12/14/2009)... Pa., Dec. 14 MODA Technology Partners, ... (EM), utility and product testing for the Pharmaceutical ... 3.0, the company,s third generation mobile data acquisition ... organizations to further automate their regulated manufacturing processes. ... capabilities: ,, Fully-Configurable Test Methods: ...
(Date:12/13/2009)... have identified plant enzymes that may help to engineer ... use water more efficiently. The finding could help to ... , Plants take in the carbon dioxide they need ... of leaves. But for each molecule of the gas ... same openings. The pores can tighten to save water ...
(Date:12/13/2009)... New Haven, Conn.A team led by Yale University ... in whole blood for the first time. Their ... online publication of Nature Nanotechnology , could ... of cancer and other diseases. , ... Professor of Engineering & Applied Science, and Tarek ...
Breaking Biology News(10 mins):MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 3Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Physicians Interactive Acquires Skyscape Inc Becoming Worlds Leading Mobile Medical Information Provider 52526 1Physicians Interactive Acquires Skyscape Inc Becoming Worlds Leading Mobile Medical Information Provider 52526 2Physicians Interactive Acquires Skyscape Inc Becoming Worlds Leading Mobile Medical Information Provider 52526 3Physicians Interactive Acquires Skyscape Inc Becoming Worlds Leading Mobile Medical Information Provider 52526 4Beta Blockers Tied to Higher Cataract Risk 52521 1Beta Blockers Tied to Higher Cataract Risk 52521 2Beta Blockers Tied to Higher Cataract Risk 52521 3Medifast Inc to Announce Second Quarter Fiscal Year 2009 Financial Results on Thursday July 30 2009 52517 1Medifast Inc to Announce Second Quarter Fiscal Year 2009 Financial Results on Thursday July 30 2009 52517 2
... Sea-viewing Wide Field-of-view Sensor (SeaWiFS) instrument settled into ... first measurements of ocean color. A decade later, ... applications and helped researchers paint a picture of ... anniversary today with briefings at the Goddard Space ...
... primates suggests that infants and children who carry a ... ill effects of fetal alcohol exposure. , Reported online ... the first evidence of a genetic risk for fetal ... by profound mental retardation in its most severe form, ...
... UT Southwestern Medical Center have found nearly 350 genes related ... much wider study in the poorly understood field of infertility. ... understand the causes of female infertility, said Dr. Diego Castrillon, ... appearing in the September issue of the journal Genetics ...
Other Biology News:NASA celebrates a decade observing climate impacts on health of world's oceans 2NASA celebrates a decade observing climate impacts on health of world's oceans 3Study reveals possible genetic risk for fetal alcohol disorders 2Study reveals possible genetic risk for fetal alcohol disorders 3UT Southwestern researchers identify hundreds of genes controlling female fertility 2
Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
... forces with the Mickle Laboratory Engineering Company ... This tissue sectioning system has been designed ... experiments and to be especially applicable to ... or from small organs. Its special features ...
Without sodium bicarbonate. Sterile, Cell culture tested...
... The Bioactive peptides are molecules of peptidic ... behaviour or activity which can be developed ... chemical and agro-food applications. In this way ... with superior properties for therapeutic applications. Primm ...
Biology Products: